GC Genome shares surge as it expands into US and Japan with AI blood test
Predicted impact: Medium
AI blood test expansion into US and Japan; no sales size given, revenue base small.
GC Genome지씨지놈
340450 · KOSDAQ · ₩340450 · 지씨지놈
₩8,440▲ ₩100 (1.20%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y +12.53%
- Market cap
- ₩200B
- Enterprise value
- ₩158B
- P/E
- 36.9×
- P/B
- 2.5×
- Dividend yield
- 0.0%
- ROE
- 6.8%
- Net margin
- 16.6%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−19.5% from the high
₩4,100Today: ₩7,890 – ₩8,800₩10,480
Returns
- 1W−15.0%
- 1M−2.7%
- 3M+93.6%
- 6M−2.8%
- YTD+23.8%
- 1Y+12.5%
- Volume today
- 809,994
- 1.0× the 20-day average
- Traded today
- ₩6.7B
- Listed shares
- 23,650,793
- EPS (12 months)
- ₩229
- Earnings yield 2.7%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 45 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Headline reports a share surge and overseas expansion plans. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat3.2% over the last month; the price is below its 20-day average.
- News impactSome1 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
GC Genome stock overview
GC Genome (지씨지놈, KRX: 340450) is listed on KOSDAQ, in the Business services sector. The company is a Korean clinical genomics firm founded in 2013 that analyzes genetic data collected at disease diagnosis and treatment sites to support early disease screening, prediction, and personalized treatment. Its shares closed at ₩8,440 on Oct 28, 2026, up 1.20% on the day, giving it a market value of ₩200B.
Key facts
- Market cap
- ₩200B
- Sector
- Business services
- Latest price change
- +1.20%
- As of
- Oct 28, 2026
- Main business
- The company is a Korean clinical genomics firm founded in 2013 that analyzes genetic data collected at disease diagnosis and treatment sites to support early disease screening, prediction, and personalized treatment.
Quick answers about GC Genome
- What does GC Genome do?
- The company is a Korean clinical genomics firm founded in 2013 that analyzes genetic data collected at disease diagnosis and treatment sites to support early disease screening, prediction, and personalized treatment. Its genetic testing services span four product groups: prenatal and newborn screening, health checkups, cancer precision diagnostics, and rare disease diagnostics, with over 300 tests offered. It sells mainly to over 1,000 hospitals and clinics in South Korea and exports tests and technology to partners in 22 countries across four regions.
- What is the market cap of GC Genome?
- The market capitalisation of GC Genome was ₩200B at the close on Oct 28, 2026.
- Who are the largest shareholders of GC Genome?
- According to the latest official filings, the largest reported holders are GC Pharma (42.56%, as of Jun 18, 2025); Ginovation No. 1 Private Investment Fund (4.04%, as of Feb 3, 2026); Gi Chang-seok (0.72%, as of Jun 18, 2025).
- When is the next earnings report from GC Genome?
- Korean companies rarely announce results dates in advance. Based on when GC Genome filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company is a Korean clinical genomics firm founded in 2013 that analyzes genetic data collected at disease diagnosis and treatment sites to support early disease screening, prediction, and personalized treatment. Its genetic testing services span four product groups: prenatal and newborn screening, health checkups, cancer precision diagnostics, and rare disease diagnostics, with over 300 tests offered. It sells mainly to over 1,000 hospitals and clinics in South Korea and exports tests and technology to partners in 22 countries across four regions.
Written by AI from the company's latest annual report.
- Korean name
- 지씨지놈
- Sector
- Business services
- Themes
- Biotech (new drugs)
- CEO
- 기창석
- Founded
- Jul 2013
- Listed
- Jun 2025
- Listed shares
- 23,650,793
- Fiscal year ends
- Month 12
- Website
- www.gcgenome.com
Similar companies
- S-1012750 · ₩3.6T₩95,100−0.21%
- Cheil Worldwide030000 · ₩2.1T₩18,510−2.63%
- Doosan Tesna131970 · ₩2T₩105,500+8.65%
- Lotte Tour Development032350 · ₩844B₩10,590+2.82%
- Soulbrain Holdings036830 · ₩791B₩38,600+2.52%
- Innocean Worldwide214320 · ₩702B₩17,560+1.15%
- Korea Ratings034950 · ₩456B₩100,500−0.30%
- Hanatour Service039130 · ₩436B₩28,150+3.87%
Recent news
[Yeouido Investment Division 1] 'SK Hynix, GC Genome' - which stocks will make the Hall of Fame?
Predicted impact: Low· Actual: 0.0% vs sector, volume 1.2× normal (5 trading days)
Stock-picking TV segment with no new company facts; similar market chatter already appeared recently.
Recent filings
See all- Half-year report (Jun 2026)Aug 14, 2026
- Quarterly report (Mar 2026)May 15, 2026
- Annual general meeting resultsMar 24, 2026
- Audit report submittedMar 16, 2026
- Annual report (Dec 2025)Mar 16, 2026
Titles in Korean until English translations are added.
Also known as: GC Genome / 지씨지놈 / 340450 / KRX:340450
Source: KRX statistical information